Compare Angi Inc (ANGI) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Angi Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Angi Inc trades at $4.5 (market cap $186.15M), while Vertex Pharmaceuticals Incorporated trades at $528.01 (market cap $132.79B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 713.3× Angi Inc's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Angi Inc nearer its low. Which is the better fit depends on your goals.
| ANGI | VRTX | |
|---|---|---|
Market Cap | $186.15M | $132.79B |
Sector | Media | Health |
52-Week High | $18.46 | $529.65 |
52-Week Low | $4.49 | $376.62 |
Enterprise Value | $395.93M | $126.92B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ANGI trades at $4.84, down 2.42% on the day, with a bearish technical signal and mixed earnings history. Revenue has declined from $1.9B in 2022 to $1.03B in 2025, though net income turned positive in 2024-2025 before a projected loss in 2026. The stock trades at low valuation multiples (P/E 14.81, P/S 0.21), but faces challenges with negative ROE and ROA. Recent news highlights Q2 2026 earnings misses and ongoing investigations into the company.
The outlook is cautious due to declining revenue, accelerating pro user churn, and negative cash flow projections. Analyst consensus is a $7.00 price target with a 'Hold' bias, but risks include platform deterioration, legal scrutiny, and lack of clear catalysts. Upside depends on stabilizing the core marketplace and executing a viable AI strategy.
Vertex Pharmaceuticals (VRTX) trades at $496.07, up 2.49% on the day, with a bullish technical signal from moving averages and strong institutional support. The company reported Q2 2026 revenue of $3.3 billion, beating estimates, and raised its full-year sales outlook, driven by cystic fibrosis treatments and newer products like CASGEVY. Financials show robust profitability with a 35% net income margin and positive cash flow trends, though recent EPS results have been mixed.
Outlook remains positive with an 84% analyst buy rating and a $534.25 consensus price target, implying upside. Key risks include execution on new product launches and competitive pressures, but solid fundamentals and raised guidance support a constructive view for investors seeking growth in biopharma.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Angi Inc
Angi Inc connects quality home service professionals across different categories, from repairing and remodeling to cleaning and landscaping, with consumers. It has two geographical segments namely North America (the United States and Canada), which primarily includes the operations HomeAdvisor, Angie's List, Handy, mHelpDesk, HomeStars, and Fixd Repair
Read more on ANGI →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
